论文部分内容阅读
我国呼吸疾病专家钟南山院士领衔的《羧甲司坦对慢性阻塞性肺疾病急性发作的作用:一项随机安慰剂对照研究》,最近以最高票数被评为国际医学权威杂志《柳叶刀》2008年度优秀论文。慢性阻塞性肺疾病(慢阻肺)是以气流受限、肺功能进行性下降为特征的疾病。流行病学资料显示,我国40岁以上人群发病率为8.2%,每年死亡人数达160万。在世界范围内,1990年慢阻肺死亡率居所有疾病死亡率的第六位。
China’s respiratory disease expert Zhong Nanshan, led by “Carboxyestatone in acute exacerbation of chronic obstructive pulmonary disease: a randomized placebo-controlled study,” recently voted the highest number of votes as the international medical authority “The Lancet” 2008 Annual outstanding paper. Chronic obstructive pulmonary disease (COPD) is a disease characterized by limited airflow and progressive decline in pulmonary function. Epidemiological data show that the incidence of over-age population in China is 8.2%, the annual death toll reached 1.6 million. Globally, COPD was the sixth leading cause of death in all countries in 1990.